Logistics	1
Module 1 - Descriptive	2
History of epi	2
Definition of epi	2
Core functions	2
Morbidity and mortality	2
Outbreak investigations and disease surveillance	3
Measures of validity and reliability	3
Module 2 - Study Designs	4
Types of populations	4
Validity in study design	4
Types of study design	4
Module 3 - Analysis and Inference	4
Measures	4
Ratios	5
Differences	5
Necessary versus sufficient	5
Epidemiological guidelines for suggesting causation	5
Chance	5
Bias	5
Confounding	5
Effect modification	6
Module 4 - Applications of Epi	6

Logistics

12/7 office hours 12-1PM 12/12 office hours 12-1PM

Look over:

- HW assignments
- Midterm exams
- Discussion slides

N-Z Hodson 210 9AM-12PM 12/13

1 double sided 3x5 index card

50MC, 3-4 guest lecture questions

Extra Tips

- Make sure to check whether a question is asking for survival or death
- For cumulative incidence, check for loss to followup

Module 1 - Descriptive

History of epi

- John Snow (cholera)
- Semmelweis (handwashing after autopsy)
- Jenner (smallpox vaccine)
- Graunt (life table)
- Lind (scurvy, controlled trial)
- Typhoid Mary [Q]

Definition of epi

• study of distribution and determinants of health-related states or events in specified populations and the application of this knowledge to the control of health problems

Core functions

- Assessment, policy development, assurance
- Prevention Primary, Secondary, Tertiary [Q]

Morbidity and mortality

- Prevalence burden of disease = pop(cases) / pop(total) [Q]
- Incidence risk of disease
 - Cumulative = new cases/total pop at risk [Q]
 - Incidence rate = new cases/total pop-time at risk [Q]
 - Assumes complete followup
- Using prevalence versus incidence [Q]
- Mortality rate
 - $\circ \quad \mathsf{All\text{-}cause} = P(deaths(total) \mid pop_{midyear}) \, \mathbf{[Q]}$
 - Cause-specific = $P(deaths(disease) | pop_{midyear})$ [Q]
- Case fatality rate severity of disease = $P(deaths \mid disease)$ [Q]
- Proportionate mortality proportion of deaths due to disease = P(death(disease) | death) [Q]
- Age-adjusted mortality rate (direct adjustment) = $\sum_{a \in age} pop(standard, age) *$

```
#deaths<sub>age</sub>
\frac{*ueatns_{age}}{pop(group,age)} / \sum_{a \in age} pop(standard, age) [Q]
```

Commented [1]: Fa18 Q23

Commented [2]: HW1 Q1-3 Sp18 Q1

Fa18 Q1

Commented [3]: Sp18 Q16 Fa18 Q18

Commented [4]: HW1 Q10

Sp18 Q20 Fa18 Q16

Commented [5]: HW1 Q9 Sp18 Q19

Fa18 Q4,17

Commented [6]: HW1 Q11,18 Sp18 Q3 F18 Q20

Commented [7]: HW1 Q7,15

Commented [8]: HW1 Q4

Sp18 Q18

Commented [9]: HW1 Q8,12

Sp18 Q4

Commented [10]: Sp18 Q5

Commented [11]: HW1 Q13-14,16

Fa18 Q5.19

- Standardized mortality ratio (indirect adjustment) = number of deaths in subpop / (mortality rate of standard * subpop) [Q] [Q]
- Observed survival
 - Life table [Q]
 - Kaplan-Meier method [Q]
 - o Life table versus Kaplan-Meier [Q]

Outbreak investigations and disease surveillance

- Endemic versus epidemic versus pandemic [Q]
- Herd immunity resistance of a group of people to a disease based on proportion of people immune to disease, applies to person-to-person transmission [Q]
- Types of outbreaks [Q]
 - o Common source
 - Point source food outbreak
 - Continuous broken fountain
 - Intermittent common flu
 - o Propagated HFM
 - Mixed
 - o Using epi curve
- Attack rate
- Identifying probable cause of outbreak [Q]
- Incubation period, via cross-tabulation [Q]
- Types of surveillance
 - o Sentinel pick certain sites
 - Syndromic between symptoms and diagnosis
 - Passive mandatory reported diseases
 - Active
 - Identify type [Q]
- Sources of data medical records, emergency departments, 911 calls, or nonclinical data from schools, labs, surveys, etc.

Measures of validity and reliability

- Validity expresses degree to which a specified measurement measures what it purports to measure, sensitive and specificity are fixed characteristics of the test, predictive values depend on the prevalence of the disease, often for new tools [Q]
 - Sensitivity = P(test positive | disease)
 - Specificity = P(test negative | no disease) [Q]
 - Net sensitivity simultaneous = inclusion exclusion
 - Net specificity simultaneous = product rule
 - Net sensitivity sequential = product rule
 - Net specificity = inclusion exclusion

Commented [12]: HW1 Q17 Sp18 Q22

Commented [13]: Age adjustment in general Fa18 Q25

Commented [14]: Sp18 Q24,25 Fa18 Q14,15

Commented [15]: HW1 Q22

Commented [16]: HW1 Q24

Commented [17]: Fa18 Q8

Commented [18]: Sp18 Q17

Commented [19]: HW2 Q2 Sp18 Q21 Fa18 Q22

Commented [20]: Sp18 Q6,7 Fa18 Q11

Commented [21]: HW2 Q1

Sp18 Q8,15 Fa18 Q10

Commented [22]: HW2 Q18

Sp18 Q10

Fa18 Q13,24

Commented [23]: ***

Commented [24]: HW2 Q8

Commented [25]: Sp18 Q11,13

 Simultaneous and sequential testing - simultaneous captures positive for either, so high sensitivity, sequential captures test negative for either, so high specificity 	
[Q]	Commented [26]: HW2 Q3,4,5 Sp18 Q14
 PPV = P(disease positive test), increases with prevalence NPV = P(no disease negative test) [Q] 	Fa18 Q2,12
NNH	Commented [27]: Sp18 Q2 Fa18 Q3
o NNT [Q]	Commented [28]: HW2 Q23
ITT [Q] Reliability - degree to which the results can be replicated for a specified measurement	Commented [29]: HW2 Q19
procedure, aka repeatability, precision, comparing one tool to itself	
o intra and inter observer agreement	6
Kappa statistic - won't have to calculate, only interpret [Q]	Commented [30]: HW2 Q6,7 Sp18 Q23
Module 2 - Study Designs	
Types of populations	
Target	
Source	
• Study	
• [Q]	Commented [31]: HW2 Q22
Validity in study design	
• Internal validity - need to consider methodological problems, bias, confounding, random	
error, must be established before generalizing to external bias	Commented [32]: HW2 Q16
External validity	
Types of study design	
Clinical Trial	
• Cohort	Commented [33]: HW2 Q11
Case control Cross-sectional	Commented [34]: HW2 Q10,13,15
Ecologic	
Identify type	Commented [35]: HW2 9, 12, 20, 21, 24, 25
	Commented [36]: HW2 Q14
Module 3 - Analysis and Inference	
,	
Measures	
 Calculate and interpret each measure Use in appropriate study design 	Commented [37]: HW3 Q5,6,7,14,1,19
● Doe in appropriate study design	Commented [38]: HW3 Q9,10

Ratios

- Relative risk (trial, cohort)
- Prevalence ratio (cross-sectional)
- Odds ratio (case control)
 - Matched and unmatched
- RR is roughly OR when disease is rare

Differences

- Risk difference
- Prevalence difference
- Attributable risk

Necessary versus sufficient

- Necessary disease won't develop w/out exposure
- Sufficient exposure guarantees disease

Epidemiological guidelines for suggesting causation

- Temporality (only one that is necessary)
- Strength of association
- Dose-response gradient
- Consistency/replication
- Coherence (biological plausibility)
- Experiment (cessation of exposure)
- Analogy
- Consideration of alternate explanations
- Specificity of association

Chance

p value, sample size, precision of confidence interval determined by sample size, type I,
 II errors

Bias

- systematic/non-random error in design, conduct or analysis of study
- Selection bias difference in characteristics between those who take part in a study versus those that do not
- Information bias flaw in data collection or measurement that results in different quality/accuracy between comparison groups
- Identify type

Confounding

Associated with exposure

Commented [39]: HW3 Q20,21

Commented [40]: HW3 Q12

Commented [41]: HW3 Q4,23

Commented [42]: HW3 Q11,13,24,25

Commented [43]: HW3 Q17,18,22

Commented [44]: HW3 Q2

Commented [45]: HW3 Q3,16

Commented [46]: HW2 Q17

- Cause of outcome
- Not in the causal pathway
- Control in study design
 - o Restriction on confounding variable
 - o Matching in a case-control study
 - $\circ \quad \text{Randomization in a clinical trial}$
- Control in the data analysis
 - $\circ \quad \textbf{Stratification}$
 - o Adjustment

Effect modification

- Make a list of potential confounders and effect modifiers
- Calculate crude measure of association for exposure and outcome of interest, calculate measures for stratified

Module 4 - Applications of Epi

Commented [47]: HW3 Q8

Commented [48]: HW3 Q1